Autologous activated macrophages (MAK) coated ex vivo with humanized anti-CD20 monoclonal antibodies can eradicate minimal residual disease in chronic lymphocytic leukaemia in clinical response

Br J Haematol. 2008 Sep;142(6):996-8. doi: 10.1111/j.1365-2141.2008.07272.x. Epub 2008 Jul 28.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / administration & dosage*
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
  • Macrophage Activation
  • Macrophages / transplantation*
  • Neoplasm, Residual
  • Rituximab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab